Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EFFIPEC trial of intensified intraperitoneal chemotherapy for colorectal cancer with peritoneal metastases
2024-516224-34-00Phase 3Authorised
- Sponsor
- Uppsala University
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of irinotecan and fluorouracil in colorectal cancer (CRC), peritoneal carcinomatosis (PC) and hepatic metastasis (3 arms), sponsored by Uppsala University. Primary endpoints: Maximum tolerated dose of 24-hour EPIC fluorouracil and Local control rate. Planned start Aug 2024; status: authorised.
02
Drugs
irinotecanfluorouracil
03
Conditions
colorectal cancer (CRC)peritoneal carcinomatosis (PC)hepatic metastasis
Beyond the preview
Go deeper on 2024-516224-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516224-34-00.